Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - PA: Cancer Research - Cancer Prevention

McMaster University

$100,000.00

Surveillance AFter Extremity Tumor surgerY (SAFETY) International Randomized Controlled Trial

EF 2020-21

Résumé
Sarcomas are cancers of the muscle and connective tissue and most commonly occur in the arms and legs (extremities). These cancers are treated with radiation and the surgical removal of the tumour. However, when the tumour is growing, cancer cells can get into the bloodstream and spread to other parts of the body. Sarcoma cells most often spread to the lungs (lung metastases). Lung metastases occur in about 50% of patients diagnosed with sarcoma, even after the tumour has been removed, and even if cancer cells were not previously seen in the lung when the patient first came to the clinic to be treated. Doctors look for lung metastases with either a chest x-ray (CXR), or CT scan of the chest. Both of these tests can show tumours once the cancer cells have formed nodules in the lung. CT scans can show smaller nodules than can CXRs. However, the nodules cannot often be safely removed and chemotherapy is ineffective. Therefore, the knowledge of the presence of the metastatic nodules in the lungs may not improve patient survival, and it may increase patient anxiety and affect quality of life. We propose a study in which sarcoma patients will be assigned by chance (randomized) to more or less frequent lung imaging (every 3 months vs. every 6 months) and to CT scans vs. CXRs. This will allow us to determine the most effective way to follow sarcoma patients in the clinic with respect to long-term survival. We will also ask patients about their anxiety when coming in to see the doctor.
Programme
Project Grant - PA: Cancer Research - Cancer Prevention
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
443062
Name
Ghert Michelle A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Randomized Controlled Trials 2
Projecttitle
Surveillance AFter Extremity Tumor surgerY (SAFETY) International Randomized Controlled Trial
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Cancer Research - Cancer Prevention
Keyworddelim
Comparative Effectiveness; Frequency; Imaging Modality; International; Randomized Controlled Trial; Sarcoma; Surveillance
Abstract
Sarcomas are cancers of the muscle and connective tissue and most commonly occur in the arms and legs (extremities). These cancers are treated with radiation and the surgical removal of the tumour. However, when the tumour is growing, cancer cells can get into the bloodstream and spread to other parts of the body. Sarcoma cells most often spread to the lungs (lung metastases). Lung metastases occur in about 50% of patients diagnosed with sarcoma, even after the tumour has been removed, and even if cancer cells were not previously seen in the lung when the patient first came to the clinic to be treated. Doctors look for lung metastases with either a chest x-ray (CXR), or CT scan of the chest. Both of these tests can show tumours once the cancer cells have formed nodules in the lung. CT scans can show smaller nodules than can CXRs. However, the nodules cannot often be safely removed and chemotherapy is ineffective. Therefore, the knowledge of the presence of the metastatic nodules in the lungs may not improve patient survival, and it may increase patient anxiety and affect quality of life. We propose a study in which sarcoma patients will be assigned by chance (randomized) to more or less frequent lung imaging (every 3 months vs. every 6 months) and to CT scans vs. CXRs. This will allow us to determine the most effective way to follow sarcoma patients in the clinic with respect to long-term survival. We will also ask patients about their anxiety when coming in to see the doctor.
Competitiondate
202010
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ghert, Michelle A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~